Published in J Hypertens on August 01, 2007
Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens (2013) 1.88
Risk stratification by 24-hour ambulatory blood pressure and estimated glomerular filtration rate in 5322 subjects from 11 populations. Hypertension (2012) 1.49
Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension (2012) 1.35
Risk stratification by self-measured home blood pressure across categories of conventional blood pressure: a participant-level meta-analysis. PLoS Med (2014) 1.29
Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol (2009) 1.26
Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens (2014) 1.25
Occupational and leisure time physical activity in contrasting relation to ambulatory blood pressure. BMC Public Health (2012) 0.98
Role of Ambulatory and Home Blood Pressure Monitoring in Clinical Practice: A Narrative Review. Ann Intern Med (2015) 0.97
Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol (2012) 0.97
Socioeconomic status, psychosocial factors, race and nocturnal blood pressure dipping in a Hispanic cohort. Am J Hypertens (2013) 0.89
Evaluation of Criteria to Detect Masked Hypertension. J Clin Hypertens (Greenwich) (2016) 0.89
Masked Hypertension and Incident Clinic Hypertension Among Blacks in the Jackson Heart Study. Hypertension (2016) 0.87
Waiting a few extra minutes before measuring blood pressure has potentially important clinical and research ramifications. J Hum Hypertens (2013) 0.86
Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension (2014) 0.86
Ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Diabetes Care (2013) 0.86
Comparing the effects of white coat hypertension and sustained hypertension on mortality in a UK primary care setting. Ann Fam Med (2008) 0.85
I Brazilian position paper on prehypertension, white coat hypertension and masked hypertension: diagnosis and management. Arq Bras Cardiol (2014) 0.84
Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. J Am Soc Hypertens (2015) 0.79
Effectiveness of olmesartan-based treatment on home and clinic blood pressure in elderly patients with masked and white coat hypertension. Hypertens Res (2014) 0.78
What is the evidence base for diagnosing hypertension and for subsequent blood pressure treatment targets in the prevention of cardiovascular disease? BMC Med (2015) 0.78
Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension? Clin Exp Nephrol (2015) 0.78
Differing pattern of ambulatory blood pressure in very elderly men expresses dynamics in atherosclerotic load in the senescence. Int J Hypertens (2011) 0.78
The Utility of Ambulatory Blood Pressure Monitoring for Diagnosing White Coat Hypertension in Older Adults. Curr Hypertens Rep (2015) 0.78
The relation of ambulatory heart rate with all-cause mortality among middle-aged men: a prospective cohort study. PLoS One (2015) 0.78
Home and Office Blood Pressure Control among Treated Hypertensive Patients in Japan: Findings from the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Pharmaceuticals (Basel) (2010) 0.75
Measurement of blood pressure. Ann Transl Med (2017) 0.75
Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension. Curr Cardiol Rep (2016) 0.75
Ambulatory blood pressure: facilitating individualized assessment of cardiovascular risk. J Hypertens (2007) 0.75
Ambulatory Blood Pressure Monitoring: A Complementary Strategy for Hypertension Diagnosis and Management in Low-Income and Middle-Income Countries. Cardiol Clin (2017) 0.75
Practical Aspects of Home and Ambulatory Blood Pressure Monitoring. Methodist Debakey Cardiovasc J (2016) 0.75
Blood Pressure Control in Hypertensive Patients, Cardiovascular Risk Profile and the Prevalence of Masked Uncontrolled Hypertension (MUCH). Med Arch (2016) 0.75
Effect of Olmesartan-Based Therapies on Therapeutic Indicators Obtained Through Out-of-Office Blood Pressure. Cardiol Ther (2015) 0.75
Ambulatory Blood Pressure Monitoring: Five Decades of More Light and Less Shadows. Arq Bras Cardiol (2016) 0.75
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens (2016) 0.75
White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens (2017) 0.75
Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring. J Stroke (2015) 0.75
Masked Hypertension: An Independent Cardiovascular Risk Factor or a Facet of True Blood Pressure Level? J Am Heart Assoc (2016) 0.75
A cyclic fluctuation model for 24-h ambulatory blood pressure monitoring in Chinese patients with mild to moderate hypertension. Acta Pharmacol Sin (2013) 0.75
Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing. Hypertension (2016) 0.75
Ambulatory blood pressure adds little to Framingham Risk Score for the primary prevention of cardiovascular disease in older men: secondary analysis of observational study data. BMJ Open (2014) 0.75
Predicted Atherosclerotic Cardiovascular Disease Risk and Masked Hypertension Among Blacks in the Jackson Heart Study. Circ Cardiovasc Qual Outcomes (2017) 0.75
Is aerobic workload positively related to ambulatory blood pressure? A cross-sectional field study among cleaners. Eur J Appl Physiol (2015) 0.75
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA (2011) 8.83
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension (2005) 5.05
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation (2011) 4.90
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation (2009) 4.78
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens (2002) 4.63
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil (2003) 4.25
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit (2002) 4.02
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Insulin resistance and risk of congestive heart failure. JAMA (2005) 3.79
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet (2010) 3.75
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med (2002) 3.61
Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension (2007) 3.57
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med (2004) 3.48
Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens (2002) 3.43
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol (2005) 3.41
Telomere length and possible link to X chromosome. Lancet (2004) 3.36
Prognosis among healthy individuals discharged with a primary diagnosis of syncope. J Am Coll Cardiol (2012) 3.33
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation (2012) 3.30
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens (2005) 3.15
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
Impact of alcohol consumption upon medical care utilization and costs in men: 4-year observation of National Health Insurance beneficiaries in Japan. Addiction (2005) 2.99
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis (2011) 2.95
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension (2005) 2.92
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90